Abstract Purpose: Neutral endopeptidase (CD10), an ectopeptidase bound to the cell surface, is thought to be a potential prognostic marker for prostate cancer. Experimental Design: Prostate cancer patients (N = 3,261) treated by radical prostatectomy at a single institution were evaluated by using tissue microarray. Follow-up data were available for 2,385 patients. The cellular domain (membranous, membranous-cytoplasmatic, and cytoplasmatic only) of CD10 expression was analyzed immunohistochemically and correlated with various clinical and histopathologic features of the tumors. Results: CD10 expression was detected in 62.2% of cancer samples and occurred preferentially in higher Gleason pattern (P < 0.0001). CD10 expression positively correlated with adverse tumor features such as elevated preoperative prostate-specific antigen (PSA), higher Gleason score, and advanced stage (P < 0.0001 each). Survival analyses showed that PSA recurrence was significantly associated with the staining pattern of CD10 expression. Outcome significantly declined from negative over membranous, membranous-cytoplasmatic, to exclusively cytoplasmatic CD10 expression (P < 0.0001). In multivariate analysis, CD10 expression was an independent predictor for PSA failure (P = 0.0343). Conclusions: CD10 expression is an unfavorable independent risk factor in prostate cancer. The subcellular location of CD10 protein is associated with specific clinical courses, suggesting an effect on different important biological properties of prostate cancer cells. The frequent expression of CD10 in prostate cancer and the strong association of CD10 with unfavorable tumor features may qualify this biomarker for targeted therapies.
Neutral endopeptidase (CD10) may be a prognostic molecular marker in prostate cancer. This enzyme is a zinc-dependent, cell surface metallopeptidase that is widely expressed in the epithelial cells of the kidney, breast, lung, intestine, and prostate gland (1) . It contains a large extracellular domain that inactivates various physiologically active peptides (e.g., bombesin, substance-P, endothelin-1) by cleavage (1) . The exact physiologic significance of CD10 is unknown. CD10 plays a part in different cancers, including prostate cancer, where it has been shown to be involved in the migration, survival, and apoptosis of cancer cells, as well as tumor progression (2) . Studies investigating the prognostic significance of the expression of CD10 in prostate cancer generated conflicting results. Zellweger et al. (3) and Freedland et al. (4) did not detect an association between CD10 expression and the recurrence of prostate-specific antigen (PSA) in prostate cancer. Osman et al. (5) reported a poor outcome for patients with CD10 loss; CD10 expression was an unfavorable risk factor in the series of Dall'Era et al. (6) .
We used an existing large-scale prostate cancer tissue microarray (7) constructed from 3,261 homogenously treated prostate cancers comprising 2,385 patients with follow-up information to further evaluate the potential prognostic significance of CD10 expression in prostate cancer. The data suggest a significant effect of the subcellular CD10 expression patterns on prostate cancer prognosis.
Materials and Methods
Patients and tissues. Radical prostatectomy specimens from 3,261 patients treated at the Department of Urology at the University Medical Center Hamburg-Eppendorf in Germany between 1992 and 2005 were available. No patient received adjuvant hormonal therapy. Additional (salvage) therapy was initiated only for biochemical relapse. Prostatectomy specimens were analyzed according to a standard procedure.
Prostates were completely embedded in paraffin (including wholemounted sections) as previously described (8) . H&E-stained histologic sections from the prostatectomy specimens were reviewed for this study. Index tumors, as defined by the largest tumor focus that is generally associated with the highest Gleason pattern (9) or the focus with the worst Gleason pattern, were marked on the slides. One tissue core of thickness 0.6 mm was punched out from the marked area of each case and transferred in a tissue microarray format as described (10) . Normal prostate tissue or prostatic intraepithelial neoplasia was not systematically sampled. Annual follow-up at the institutional outpatient clinic (University Medical Center Hamburg-Eppendorf) was scheduled. Information about external posttreatment PSA testing (usually done every 6 months) was added to the institutional database. Follow-up data for 2,385 patients, ranging from 1 to 144 mo (mean 34.9 mo), were available. PSA failure was defined as persisting or increasing postoperative PSA (>0.1 ng/mL).
Immunohistochemistry. Freshly cut tissue microarray sections were analyzed in 1 d in one experiment. High-temperature pretreatment of slides was done in steam with target retrieval solution (pH 9; Dako). CD10 expression was assessed using the monoclonal antibody CD10 (clone 56C6; Novocastra). Optimal staining was achieved at 1:50 antibody dilution. Bound primary antibodies were visualized using the Envision Plus system (Dako). CD10 expression profile (negative, membranous, membranous-cytoplasmatic, and cytoplasmatic only) was determined. CD10 expression on the spot was homogenous in the vast majority of cases as previously reported (5) . The cases with a heterogeneous CD10 expression were classified according to the cell population with the most extensive CD10 expression. The proportion of these cells and staining intensity were not considered for analyses. Normal glands were the positive internal controls.
Statistical analyses. Statistical calculations were done with PRISM 2.01 software (GraphPad). Contingency tables were calculated using m 2 test and Fisher's exact test. Survival curves were plotted by the KaplanMeier method and compared with the log-rank test. Cox regression was used to assess independence of preoperative parameters, histopathologic features, and immunohistochemical staining to predict PSA recurrence after radical prostatectomy.
Results
Patient data. Comprehensive clinical and histopathologic data are given in Table 1 .
Technical issue. Five hundred and thirty-seven cancer samples were lost for immunohistochemical analyses due to lack of tissue spots or absence of unequivocal cancer tissue in the immunostained tissue microarray section.
Immunohistochemical results and univariate survival analysis of CD10. Detectable CD10 expression was seen in 62.2% (1,695 of 2,724) of all cancer spots. CD10 + cases showed distinctly different staining patterns. Staining was exclusively membranous (Fig. 1A ) without obvious cytoplasmatic immunoreactivity in 30.5% of cases. In glandular cancer tissue of Gleason patterns 3 and 4, membranous reactivity was generally limited to the apical aspect of the cells outlining the lumen whereas membranous staining in Gleason pattern 5 cases (n = 12) was circumferential and complete. Membranous and additionally cytoplasmatic stainings (Fig. 1B) , the latter mainly partially and in the submembranous apical region, were observed in 24.7% of cases; the reaction pattern was diffusely cytoplasmatic without evident membranous accentuation in 7.0% of cases (Fig. 1C) . The frequency of CD10 expression significantly increased with higher Gleason pattern (GP3: 58.7%; GP4: 74.2%; GP5: 75%; P < 0.0001; Fig. 2 ). Separate analysis of the patterns of CD10 staining showed that membranous CD10 staining predominated in Gleason pattern 3, whereas cytoplasmatic staining preferentially occurred in higher Gleason pattern. CD10 expression was linked to unfavorable features of tumors, such as elevated preoperative PSA and advanced stage (P < 0.0001 each; Table 2 ).
Patients with CD10 expression were at significantly increased risk for PSA recurrence (P < 0.0001) compared with patients 
Translational Relevance
This is the first study evaluating the prognostic effect of CD10 expression in different subcellular compartments in prostate cancer. The large scale of 3,261 prostate cancer patients treated by radical prostatectomy at a single institution allowed detecting CD10 expression as an independent adverse risk factor that might also qualify for risk stratification in the biopsy setting. Survival of the CD10 + patients can be further stratified by the subcellular location of CD10 expression. These findings suggest that the subcellular location of CD10 protein significantly affects important biological properties of prostate cancer cells. The frequent expression of CD10 in prostate cancer and the strong association of CD10 with unfavorable tumor features may qualify this biomarker for targeted therapies. without CD10 expression. This increased risk could be further stratified by the different subcellular CD10 expression pattern (P < 0.0001; Fig. 3 ). The risk of PSA recurrence increased from lack of CD10 expression over membranous, membranouscytoplasmatic, to exclusively cytoplasmatic expression.
Multivariate analysis of prognostic factors. Multivariate analysis for PSA recurrence-free survival (Table 3) included preoperative PSA, Gleason score, tumor stage, and CD10 immunostaining. CD10 expression independently predicted PSA failure (P = 0.0343) together with preoperative PSA, Gleason score, and tumor stage (P < 0.0001 each). The hazard ratio of 1.10 indicated a 10% elevated risk of PSA failure for patients with CD10 expression compared with those without CD10 expression.
Discussion
CD10, a cell surface ectopeptidase that can inactivate extracellular peptides, is thought to have a role in prostate cancer; however, the results are conflicting: Increased expression of CD10 in higher Gleason grades (5, 6, 11) and in lymph node metastases from prostate cancer (12) indicated a role for CD10 expression in cancer progression. Functional studies using cell lines showed the antitumor effects of CD10, including inhibition of the migration, growth, and survival of cells (2) . However, conclusions drawn from single cell lines might not appropriately reflect in vivo findings in large cohorts of hormone-naBve patients. The percentage of CD10 + cancers in our tissue microarray was 62.2%, comparable with the 66% reported for another hormone-naBve prostate cancer tissue microarray (4) . Studies on the prognostic potential of CD10 in human prostate cancer samples have provided conflicting data, describing CD10 expression to be a favorable (5), unfavorable (6), and not a risk factor (3, 4) . The comparability of these results may be limited due to differences between the evaluated cohorts. The better outcome for CD10 + patients reported by Osman et al. (5) was detected in a cohort of 223 mainly African-American men with significant race-dependent differences in CD10 expression. It is unclear if the constitution of this cohort contributed to these results. Zellweger et al. (3) evaluated a cohort of 551 heterogeneously treated patients (radical prostatectomy or transurethral resection) composed of 101 patients with neoadjuvant hormonal therapy; their study showed a statistically nonsignificant trend for adverse outcome in CD10 + patients. Our finding of CD10 expression as an unfavorable risk factor in a homogeneously treated population of 2,385 prostate cancer patients with follow-up data is in accordance with findings reported by Dall'Era et al. (6) obtained from 87 prostate cancers. CD10 expression was not only associated with unfavorable risk factors like high preoperative PSA, Gleason score, and tumor stage, but it also added independent prognostic information beyond that obtained from these traditional risk factors. Our data suggest that the pattern of subcellular CD10 expression has biological significance. PSA recurrence -free survival significantly declines from membranous over membranous-cytoplasmatic to exclusively cytoplasmatic CD10 expression.
Little is known about the exact regulation of CD10 expression in prostate cancer. There is evidence that androgens induce CD10 expression (13) and that translation of the CD10 gene is regulated by methylation of the gene promoter (14) . There is no evidence for mutations in the CD10 gene in prostate cancer, indicating the expression of functional proteins. The different patterns of subcellular expression of the CD10 protein in prostate cancer, including cytoplasmatic localization, have been described previously (15 -17) . Functional studies using prostate cancer cell lines transfected with differentially constructed inserts suggest that motifs on the COOH terminus and the NH 2 terminus of CD10 cDNA may determine the subcellular location of CD10 expression (18) . Internalization of membrane-bound CD10, as shown in malignant cell lines of B lineage (19) , or an association of CD10 with intracytoplasmatic heat shock proteins (20) might also contribute to cytoplasmatic staining; however, the mechanism of this phenomenon is obscure (20) .
The complexities of cell surface ectopeptidases and their role in various cancers are incompletely understood (21) . Ectopeptidases possess biological activity independent of their wellknown enzymatic property of processing extracellular peptides (21) . Membrane-bound and cytoplasmatic CD10 expression may have different functions in the molecular mechanism of prostate cancer (22) . Conceivably, membranous CD10 in prostate cancer in vivo primarily inactivates inhibitory peptides, thus promoting tumor growth. Alternatively, the enzymatic activity of CD10 could promote tumor growth by conversion of a propeptide into a biologically active, stimulatory form. These (25, 26) may be applied to counteract the unfavorable effects of CD10 on survival. Second, CD10 can process peptide prodrugs, increasing their cytotoxic potency on CD10-expressing tumor cells 100-to 300-fold (27) . This antitumor effect has been applied successfully in a xenograft model using a prostate cancer cell line that overexpresses CD10 (27) .
In conclusion, CD10 expression is an unfavorable independent risk factor in prostate cancer. The effect on prognosis of the subcellular location of CD10 suggests substantial biological differences between tumor cells with membranous and cytoplasmatic CD10 deposits. CD10 expression in prostate cancer may be used as a therapeutic target for adjuvant therapies.
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